477 related articles for article (PubMed ID: 12034361)
1. ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation.
Feroz K; Williams E; Riese DJ
Cell Signal; 2002 Sep; 14(9):793-8. PubMed ID: 12034361
[TBL] [Abstract][Full Text] [Related]
2. Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners.
Li Z; Mei Y; Liu X; Zhou M
Cell Signal; 2007 Mar; 19(3):466-71. PubMed ID: 16978839
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors.
Alimandi M; Wang LM; Bottaro D; Lee CC; Kuo A; Frankel M; Fedi P; Tang C; Lippman M; Pierce JH
EMBO J; 1997 Sep; 16(18):5608-17. PubMed ID: 9312020
[TBL] [Abstract][Full Text] [Related]
4. Betacellulin and amphiregulin induce upregulation of cyclin D1 and DNA synthesis activity through differential signaling pathways in vascular smooth muscle cells.
Shin HS; Lee HJ; Nishida M; Lee MS; Tamura R; Yamashita S; Matsuzawa Y; Lee IK; Koh GY
Circ Res; 2003 Aug; 93(4):302-10. PubMed ID: 12869389
[TBL] [Abstract][Full Text] [Related]
5. ErbB receptors mediate both migratory and proliferative activities in human melanocytes and melanoma cells.
Gordon-Thomson C; Jones J; Mason RS; Moore GP
Melanoma Res; 2005 Feb; 15(1):21-8. PubMed ID: 15714117
[TBL] [Abstract][Full Text] [Related]
6. Cell death induced by TNF or serum starvation is independent of ErbB receptor signaling in MCF-7 breast carcinoma cells.
Egeblad M; Jäättelä M
Int J Cancer; 2000 Jun; 86(5):617-25. PubMed ID: 10797281
[TBL] [Abstract][Full Text] [Related]
7. The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand.
Bouyain S; Longo PA; Li S; Ferguson KM; Leahy DJ
Proc Natl Acad Sci U S A; 2005 Oct; 102(42):15024-9. PubMed ID: 16203964
[TBL] [Abstract][Full Text] [Related]
8. Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines.
Mill CP; Gettinger KL; Riese DJ
Exp Cell Res; 2011 Feb; 317(4):392-404. PubMed ID: 21110957
[TBL] [Abstract][Full Text] [Related]
9. Heregulin (HRG)-induced mitogenic signaling and cytotoxic activity of a HRG/PE40 ligand toxin in human breast cancer cells.
Fiddes RJ; Janes PW; Sanderson GM; Sivertsen SP; Sutherland RL; Daly RJ
Cell Growth Differ; 1995 Dec; 6(12):1567-77. PubMed ID: 9019162
[TBL] [Abstract][Full Text] [Related]
10. ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB4.
Wang LM; Kuo A; Alimandi M; Veri MC; Lee CC; Kapoor V; Ellmore N; Chen XH; Pierce JH
Proc Natl Acad Sci U S A; 1998 Jun; 95(12):6809-14. PubMed ID: 9618494
[TBL] [Abstract][Full Text] [Related]
11. Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation.
Contessa JN; Abell A; Mikkelsen RB; Valerie K; Schmidt-Ullrich RK
Breast Cancer Res Treat; 2006 Jan; 95(1):17-27. PubMed ID: 16267617
[TBL] [Abstract][Full Text] [Related]
12. Biological response to ErbB ligands in nontransformed cell lines correlates with a specific pattern of receptor expression.
Sundaresan S; Roberts PE; King KL; Sliwkowski MX; Mather JP
Endocrinology; 1998 Dec; 139(12):4756-64. PubMed ID: 9832411
[TBL] [Abstract][Full Text] [Related]
13. Ligand discrimination in signaling through an ErbB4 receptor homodimer.
Sweeney C; Lai C; Riese DJ; Diamonti AJ; Cantley LC; Carraway KL
J Biol Chem; 2000 Jun; 275(26):19803-7. PubMed ID: 10867024
[TBL] [Abstract][Full Text] [Related]
14. Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling.
Wandinger SK; Lahortiga I; Jacobs K; Klammer M; Jordan N; Elschenbroich S; Parade M; Jacoby E; Linders JT; Brehmer D; Cools J; Daub H
PLoS One; 2016; 11(1):e0146100. PubMed ID: 26745281
[TBL] [Abstract][Full Text] [Related]
15. [Establishment of an ErbB3- and ErbB4-specific ligand screening system, and a screen of neuregulin-1 mutants].
Qi Y; Wei DZ; Liu XF; Zhou MD
Yi Chuan; 2010 Dec; 32(12):1247-55. PubMed ID: 21513150
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
17. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.
Lee H; Akita RW; Sliwkowski MX; Maihle NJ
Cancer Res; 2001 Jun; 61(11):4467-73. PubMed ID: 11389077
[TBL] [Abstract][Full Text] [Related]
18. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
19. Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4.
Fitzpatrick VD; Pisacane PI; Vandlen RL; Sliwkowski MX
FEBS Lett; 1998 Jul; 431(1):102-6. PubMed ID: 9684874
[TBL] [Abstract][Full Text] [Related]
20. An ERBB3/ERBB2 oncogenic unit plays a key role in NRG1 signaling and melanoma cell growth and survival.
Zhang K; Wong P; Duan J; Jacobs B; Borden EC; Bedogni B
Pigment Cell Melanoma Res; 2013 May; 26(3):408-14. PubMed ID: 23480537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
